XML 52 R36.htm IDEA: XBRL DOCUMENT v3.26.1
Related Party Transactions (Tables)
6 Months Ended
Jun. 30, 2026
Related Party Transactions  
Schedule of common stock sold to related parties

As part of the registered direct offering, the following number of shares of common stock, pre-funded warrants and common warrants were sold to related parties:

  ​ ​ ​

Number of

Number of

  ​ ​ ​

Number of

Aggregate

Shares of

Pre-Funded

Common

Purchase

  ​ ​ ​

Common Stock

  ​ ​ ​

Warrants

  ​ ​ ​

Warrants

  ​ ​ ​

Price

OrbiMed Advisors LLC (1)

1,444,085

1,397,684

$

2,499,856

Puissance Capital Management (2)

866,451

838,610

1,500,000

Richard A. Miller, M.D. (3)

577,634

559,073

1,000,000

William B. Jones, Ph.D. (4)

20,001

19,357

34,624

(1)Peter Thompson, M.D., a member of the Company’s Board of Directors since November 2014, is a Private Equity Partner at OrbiMed Advisors, LLC.
(2)Ted Wang, Ph.D., a Co-Founder, General Manager and Director of Angel Pharmaceuticals, of which the Company holds a 49% ownership interest, is the founder of Puissance Capital Management.
(3)Richard A. Miller, M.D. is the Company’s President, Chief Executive Officer and Chairman of the Board of Directors.
(4)William B. Jones, Ph.D. is the Company’s Senior Vice President, Pharmaceutical Development.

During the three months ended June 30, 2025, all of the common warrants sold to related parties as part of the Company’s May 2024 registered direct offering were exercised. The details of these exercises are as follows:

  ​ ​ ​

Number of

Number of

Common Shares

Aggregate

Common Warrants

Issued Upon

Proceeds Received

  ​ ​ ​

Exercised

  ​ ​ ​

Exercise

  ​ ​ ​

Upon Exercise

OrbiMed Advisors LLC (1)

1,397,684

221,352

$

Puissance Capital Management

838,610

838,610

2,935,135

Richard A. Miller, M.D.

559,073

559,073

1,956,756

William B. Jones, Ph.D.

19,357

19,357

67,750

(1)OrbiMed Advisors LLC paid the exercise price of $3.50 per common stock warrant on a cashless basis, resulting in the Company withholding 1,176,332 of the warrant shares to pay the exercise price and issuing to OrbiMed Advisors LLC the remaining 221,352 shares. This transaction is considered a non-cash financing activity.